A nurse holds a syringe containing a vaccine against coronavirus disease (COVID-19) produced by the Beijing Institute of Biological Products, a unit of the Sinopharm China National Biotec Group (CNBG), at a vaccination center during an organized visit Government, Beijing, China, April 15, 2021. REUTERS / Thomas Peter
The World Health Organization will decide later this month or in May on the emergency use lists for COVID-19 vaccines from Sinopharm (1099.HK) and Sinovac (SVA.O) following an extensive review, it said on Thursday. an official of the WHO European region.
“We are in touch with them to analyze the dossiers that have been submitted by both vaccine manufacturers,” Siddhartha Datta, a WHO-Europe vaccination expert, told a virtual news conference. “We will hear about a decision to list emergency uses in April or early May, so please keep that in mind.”
A WHO group in the final stages of reviewing Chinese vaccines said a decision for at least one could come on April 26, while a second meeting was scheduled for May 3, if more time was needed to make a decision on both fires.
Such a WHO emergency list is a prerequisite for the COVAX vaccine sharing facility designed to take photos in poorer countries. It also helps countries with less developed regulatory systems about the safety and effectiveness of a vaccine.
To date, WHO has issued emergency lists for the COFID-19 Pfizer and BioNTech vaccine (22UAy.DE), as well as versions of the AstraZeneca (AZN.L) vaccine developed by the Serum Institute of India and South Korea AstraZeneca-SKBio.
The CanSino vaccine relies on a viral vector to provide DNA to determine an immune response, a technique similar to that used in both AstraZeneca and Johnson & Johnson (JNJ.N) vaccines, which are now being investigated for their association with very rare blood clots, combined with low platelets. it matters.
CanSino said there were no reports of blood clots. Read more
The Sinovac vaccine, used in places like Hong Kong and Brazil, relies on inactivated coronaviruses to generate an immune response, a technique used for decades, including against polio. Read more
Our standards: Thomson Reuters’ principles of trust.